Itraconazole injection

Pharmacotherapeutic classification: J02AC02 (systemic antifungal, triazole derivatives). Itraconazole is a triazole derivative with broad-spectrum antifungal activity. In vitro tests have shown that itraconazole can inhibit the growth of a variety of human pathogenic fungi within the conventional dose range (le; 0.025 micro; g / ml to 0.8 micro; g / ml), including: dermatophytes (Trichophyton, Microsporum, Epidermophyton floccosum), yeasts (Candida including Candida albicans, Candida glabrata and Candida krusei; Cryptococcus neoformans; Malassezia; Trichosporon; Geotrichum), Aspergillus, Histoplasma, Paracoccidioides brasiliensis, Sporothrix schenckii, Chromosporium, Cladosporium, Blastomyces dermatitidis, Pseudomonas boydii, Penicillium marneffei and many other yeasts and fungi; Candida krusei, Candida glabrata and Candida tropicalis are usually the Candida strains with the lowest sensitivity. In in vitro tests, individual tests showed significant resistance to itraconazole. The main fungi not inhibited by itraconazole are Zygomycetes (Schizomycetes, Rhizomucor, Mucor and Absidia), Fusarium, Scedosporium and Scopulariopsis. The results of in vitro studies showed that itraconazole can disrupt the synthesis of ergosterol in fungal cell membranes. Ergosterol is an important component of fungal cell membranes. Interfering with its synthesis will ultimately produce antifungal effects.

This product can be used for empirical treatment of patients with neutropenia and fever suspected of fungal infection. This product can also be used to treat the following systemic fungal infections: 1. Aspergillosis. 2. Candidiasis. 3. Cryptococcal disease (including cryptococcal meningitis); for immunocompromised patients with cryptococcosis and all patients with central nervous system cryptococcosis, this product can only be used for treatment when first-line drugs are not applicable or ineffective; 4. Histoplasmosis. Before treatment, fungal specimens should be collected and other relevant laboratory tests (wet smears, histopathology, serology) should be performed to isolate and identify pathogenic microorganisms. Treatment can be carried out before the results of culture and other laboratory tests are obtained; once meaningful test results are obtained, antifungal treatment should be adjusted accordingly.

Itraconazole injection is given twice a day for the first two days, and then once a day. Treatment for the first and second days: 200 mg of itraconazole is given by intravenous drip twice a day for 1 hour each time. From the third day onwards: 200 mg of itraconazole is given by intravenous drip once a day for 1 hour each time. The safety of intravenous medication for more than 14 days is unknown.

1. Common gastrointestinal discomfort, such as anorexia, nausea, abdominal pain and constipation. 2. Less common side effects include headache, elevated reversible aminotransferase, menstrual disorders, dizziness and allergic reactions (such as itching, erythema, wheals and angioedema). 3. There are case reports of Stevens-Johnson syndrome (severe erythema multiforme). 4. Most patients with underlying pathological changes who are receiving multiple drug treatments at the same time may experience symptoms such as hypokalemia, edema, hepatitis and alopecia when receiving long-term treatment with itraconazole. 5. There are case reports of peripheral neuropathy, but it is not certain whether it is related to the use of itraconazole.

25 ml: 0.25 g